Jinxin Fertility Group Limited (abbreviated as JXR) released an update on its three-year Shareholder Return Plan covering 2026–2028, reaffirming its commitment to distribute 50 %–80 % of annual non-IFRS adjusted EBITDA through a mix of share repurchases and cash dividends.

Over the past 12 months, JXR has: • Declared and paid dividends of approximately RMB100.00 million (HKD109.70 million) for FY2025. • Repurchased 162.609 million shares in the open market for about RMB328.90 million (HKD373.60 million).

The Board previously authorized up to RMB300.00 million in buybacks within 12 months; management now plans to continue repurchasing shares in 2026, citing strong cash flow and a belief that the current share price undervalues the business.

Dividend Outlook Management aims to lift cash‐dividend distributions to 20 %–40 % of annual non-IFRS adjusted EBITDA once the share price better reflects intrinsic value. For illustration, trailing 12-month non-IFRS adjusted EBITDA to 30 June 2026 was RMB602.90 million. Applying the targeted payout range would imply dividends of roughly RMB120.60 million to RMB241.20 million, though any actual distribution remains subject to Board approval, general-meeting votes, capital needs, and progress at Shenzhen Zhongshan Obstetrics and Gynecology Hospital and other strategic projects.

The company emphasized that all repurchase and dividend actions depend on market conditions, regulatory approvals, and ongoing assessment of its financial position. Shareholders and investors are advised to exercise caution when dealing in JXR securities.